Table 4.
Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|
Risk factor | OR (95% CI) | p-value | OR (95% CI) | p-value |
Male gender (vs. Female) | 4.25 (0.53-33.61) | 0.17 | ||
Age ≥70 years (vs. ≤69 years) | 1.45 (0.38-5.57) | 0.58 | ||
Tumor location Lower (vs. Upper and Middle) | 2.36 (0.68-8.20) | 0.17 | ||
Continued use of LDA | 3.66 (0.74-17.93) | 0.11 | ||
Continued use of LDA + heparin replacement | 13.30 (1.27-139.25) | 0.03* | 32.88 (2.61-414.05) | <0.01* |
Heparin replacement | 3.50 (0.71-17.10) | 0.12 | ||
Cessation of antithrombotic agent during ESD procedure (vs. No antithrombotic therapy) | 3.08 (0.60-15.87) | 0.18 | ||
Liver cirrhosis | 1.33 (0.16-10.81) | 0.78 | ||
CKD undergoing hemodialysis | 4.92 (0.56-43.20) | 0.15 | ||
Specimen size ≥40 mm (vs. < 40 mm) | 6.08 (1.74-21.27) | <0.01* | 8.03 (2.03-31.72) | <0.01* |
Procedure time ≥90 min (vs. < 90 min) | 3.44 (0.81-14.71) | 0.10 | ||
Second-look endoscopy (vs. No second-look endoscopy) | 1.96 (0.24-15.60) | 0.52 |
OR: Odds ratio.
CI: Confidence interval.
LDA: Low-dose aspirin.
CKD: Chronic kidney disease.
*p<0.05.